Join the discussion.


Recent Webinars

Hereditary cancer limited-evidence genes: What are they?

Michael Anderson, PhD and Daniela Iacoboni, MS, LCGC
November 04, 2015
Series: ZinniaEntrySeries object
View Recording

With the recent launch of new panels and genes, Invitae has introduced a new category of genes: limited-evidence genes. Invitae has rigorously evaluated the literature to determine whether an association between the gene and specific condition has been established. In this webinar, we will review cases explaining the groupings of specific panels and the evidence.

Cardiovascular genetic testing with Invitae

Nicole M. Johnson, ScM, LCGC, Invitae Genetic Counselor
October 19, 2015
View Recording

Invitae is making high-quality cardiovascular genetic testing faster and more affordable than ever before. Our expanded test menu includes broad, comprehensive, and combined panels, as well as single-gene tests.

In this webinar, Invitae genetic counselor Nicole M. Johnson describes our new cardiovascular offerings as well as our flexible menu, with which you can easily select a pre-curated panel, combine multiple panels, or customize your own panel with one click. Our affordable and transparent pricing allows you to choose the right genes for your patient, knowing exactly what it will cost.

Invitae’s team of medical and genetic experts combines full-gene next-generation sequencing and exonic copy number analysis with rigorous evidence-based variant classification methods to provide clearly interpreted diagnostic results.

Full PMS2 at Invitae: cheaper, faster, better

Federico Monzon, MD, FCAP Dan Kvitek, PhD
August 18, 2015
View Recording

Sequencing the PMS2 gene is difficult. Accurately analyzing complex portions of this gene for sequence and del/dup variants usually requires expensive and complex lab techniques. We have developed a method for full PMS2 sequencing and deletion/duplication analysis that offers both the same high quality and the same affordable price you’ve come to expect from Invitae.

Our new, highly accurate method covers both PMS2 and its pseudogene, PMS2CL. The trick lies in evaluating all reads from both genes as if they belonged only to PMS2, and then using a bioinformatic screen to call variants across this region. In cases where no variants are found, the sample can continue through the testing process. In cases with positive screen findings, we use alternate technologies to determine whether the variant is in PMS2 or PMS2CL.

Join our webinar to learn about Invitae’s innovative approach to PMS2 exons 12-15, including how we thoroughly validated this process.

A clinical genetics exploration of Charcot-Marie-Tooth disease

Carly Siskind, MS, CGCL, Stanford Health Care
July 29, 2015
Series: ZinniaEntrySeries object
View Recording

Charcot-Marie-Tooth disease (CMT) is a group of hereditary neuropathies that is characterized by weakness of the foot and lower leg muscles. Symptoms are caused by an impairment in the ability of peripheral nerves to conduct signals throughout the body and result in reduced motor control and sensation in the arms and legs. Different subtypes of CMT exist and genetic testing is often needed to identify the specific subtype. In this webinar, licensed genetic counselor Carly Siskind will explore the underlying genetics, diagnostic options, and clinical management strategies for CMT. She will also discuss the CMT Association and its role as a support resource for clinicians and for patients who are managing this progressive condition.

Assessing clinical utility of multi-gene panel tests to improve cancer care

Steve Lincoln
July 01, 2015
Series: ZinniaEntrySeries object
View Recording

Testing panels of hereditary cancer genes represents an important advance in medicine; however, the clinical impact of these tests is not yet fully understood. In this webinar, we will discuss a recent study on the clinical utility of panel testing in hereditary breast and ovarian cancer patients, presented at the American Society of Clinical Oncology meeting on June 1, 2015. 
More than 1,000 BRCA1/BRCA2-negative individuals who met appropriate criteria for BRCA testing were studied. Of the 63 who carried non-BRCA mutations, the patient management implications of these findings were assessed under uniform criteria based on current practice guidelines. The study found that the majority of non-BRCA positive results would warrant consideration of a change in care for the patient, over and above any actions that would be considered based on personal and family history alone. Moreover, the study showed that genetic testing of family members would also be warranted given the management implications for relatives who tested positive for these non-BRCA genes. 

These results show that panel testing can yield clinically relevant and actionable findings with potentially beneficial management impact for substantially more patients than BRCA1/BRCA2 testing alone can. 

The study was conducted as a collaboration between Invitae, Massachusetts General Hospital, the Stanford Cancer Institute, and Beth Israel Deaconess Medical Center.

Sherloc: A weighted, score-based variant classification system based on the 2015 ACMG ISV guidelines

Keith Nykamp, Ph.D.
June 24, 2015
Series: ZinniaEntrySeries object
View Recording

With increasing use of high-throughput sequencing and multi-gene panels for diagnostic purposes, there is growing concern about the potential for inconsistent variant classifications among clinical labs. The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) recently drafted new standards and guidelines for the interpretation of sequence variants (ISV) to address this concern. Draft versions of these guidelines were shared broadly with the clinical genetics community, feedback was incorporated, and an evidence-based checklist for interpreting Mendelian disease variants has now been published (Richards et al., Genet Med 2015). This checklist represents a major step toward evidence-assessment standardization and variant-classification consistency. However, many ISV criteria are quite expansive, which could result in inconsistency in their application. To date, a rigorous study has not been published examining the impact of these new guidelines on variant classification and clinical reporting. It also remains to be seen whether the new evidence checklist results in increased interpretation concordance between clinical laboratories. We considered these issues when validating our own laboratory’s classification procedures, which are based on the new ISV guidelines.

With the 2015 ACMG ISV guidelines as our guide, we developed Sherloc, a score-based classification system with detailed evidence criteria, inherent logic for handling interdependent evidence, and comprehensive notes outlining caveats, various use cases, and evidence considerations for each criteria. This system has been implemented in our clinical-testing workflow and refined over the past 20 months. To evaluate the concordance of Sherloc classifications with current community standards, we compared classifications of over 800 variants to a consensus classification derived from ClinVar submissions. Importantly, we find Sherloc interpretations to be  highly consistent with those submitted to ClinVar.

Diagnosis and management of hypertrophic cardiomyopathy

Dr. Christopher Semsarian, Director, Genetic Heart Disease and Hypertrophic Cardiomyopathy Clinic at Royal Prince Alfred Hospital, Sydney; Director, Australian Genetic Heart Disease Registry
May 18, 2015
Series: ZinniaEntrySeries object
View Recording

Hypertrophic cardiomyopathy (HCM) is one of the most common single-gene inherited cardiovascular conditions and the most common cause of sudden cardiac death in athletes in the United States. It can present anytime from infancy through adulthood.

Defined by unexplained, abnormal thickening of the heart muscle, or myocardium, HCM can impair both how the heart contracts and the heart’s electrical system, leading to palpitations, dizziness, fainting, chest pain, shortness of breath, and, in some cases, sudden cardiac arrest or death.

Individuals with clinical symptoms of HCM may benefit from diagnostic genetic testing to better understand risks, confirm a diagnosis, and inform management. Asymptomatic individuals within a family with a known HCM mutation may also benefit, as testing may clarify their personal risk of developing HCM and allow for the consideration of medical management.

In this webinar, internationally renowned cardiologist and scientist Dr. Christopher Semsarian offers an overview of the diagnosis and management of HCM from a molecular, genetic, and clinical perspective, and discusses published HCM guidelines.

Next-generation sequencing (NGS) panel testing for Noonan spectrum and related RASopathy disorders

Britt Johnson, PhD, FACMG, Invitae Medical Team
April 21, 2015
Series: ZinniaEntrySeries object
View Recording

Noonan syndrome is a genetic condition, often identified at birth, that can be characterized by a wide spectrum of symptoms and physical features. Clinical findings of Noonan syndrome (and related disorders) include congenital heart defects, craniofacial features, cutaneous abnormalities, tumor development, and more. Noonan spectrum disorders are known as RASopathies due to their impact on the RAS-mitogen-activated protein kinase (MAPK) intracellular signaling pathway. Invitae offers panel testing for conditions that fall under this spectrum.

In this webinar, Britt Johnson will describe both the underlying genetics, as well as the laboratory offerings relevant to obtaining a diagnosis for patients presenting with these clinical features.

Hereditary gynecologic cancers: An overview and case studies

Tali Ekstein, MS, LCGC, Invitae
April 01, 2015
Series: ZinniaEntrySeries object
View Recording

As many as 5 to 15% of gynecological cancers are inherited. In this webinar, Invitae’s genetic counselor, Tali Ekstein, will review Invitae’s Hereditary Gynecologic Cancers Panel. We will discuss when this panel may be considered, review the key genes, and cover case studies related to ovarian and endometrial cancers. We will also review how the information obtained from genetic testing may benefit your patient and their family members.


The underlying genetics of Joubert syndrome, featuring the Joubert Syndrome & Related Disorders Foundation

Dana Knutzen, MS, LCGC
March 19, 2015
Series: ZinniaEntrySeries object
View Recording

Joubert syndrome is a genetic condition that is characterized by congenital malformations of the brain stem and an absence or underdevelopment of the cerebellar vermis (cerebellar vermis hypoplasia). This disorder usually manifests in early childhood and includes a spectrum of neurological symptoms, including hypotonia, developmental delay, breathing abnormalities (e.g., episodic tachypnea-apnea), atypical eye movements (e.g., oculomotor apraxia), and progressive truncal ataxia. Joubert syndrome presents with different disease severities and different symptoms, including retinal disease, renal disease, oculorenal disease, hepatic disease and oro-facial-digital features. From a genetic perspective, it is a complex disorder. 

In this webinar, genetic counselor Dana Knutzen will present the fundamentals of Joubert syndrome genetics while also describing her own professional experiences with this condition, particularly in the context of her advocacy work with the Joubert Syndrome & Related Disorders Foundation.